michigan hypertension core curriculum - State of Michigan

therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB
therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. J Investig Med
2008; 56(4): 714-719.
11. Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R et al. Selective
aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin
J Am Soc Nephrol 2006; 1(5): 940-951.
12. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J et al. Renal outcomes with
telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre,
randomised, double-blind, controlled trial.[see comment]. Lancet 2008; 372(9638): 547-553.
13. Krolewski M, Eggers PW, Warram JH. Magnitude of end-stage renal disease in IDDM: a 35 year
follow-up study.[erratum appears in Kidney Int 1997 Mar;51(3):978]. Kidney Int 1996; 50(6): 2041-
2046.
14. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme
inhibition on diabetic nephropathy. The Collaborative Study Group.[see comment][erratum
appears in N Engl J Med 1993 Jan 13;330(2):152]. N Engl J Med 1993; 329(20): 1456-1462.
15. Kunz R, Friedrich C, Wolbers M, Mann JF, Kunz R, Friedrich C et al. Meta-analysis: effect of
monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria
in renal disease.[see comment]. Ann Intern Med 2008; 148(1): 30-48.
16. Haas M, Leko-Mohr Z, Erler C, Mayer G, Haas M, Leko-Mohr Z et al. Antiproteinuric versus
antihypertensive effects of high-dose ACE inhibitor therapy.[see comment]. Am J Kidney Dis
2002; 40(3): 458-463.
17. Navis G, Kramer AB, de Jong PE, Navis G, Kramer AB, de Jong PE. High-dose ACE inhibition:
can it improve renoprotection?[comment]. Am J Kidney Dis 2002; 40(3): 664-666.
18. Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A, Bakris GL et al. Differential effects of
calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004; 65(6):
1991-2002.
19. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG et al. Blood pressure
control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal
Disease Study. Ann Intern Med 1995; 123(10): 754-762.
20. Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J et al. The relationship between
magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African
American study of kidney disease and hypertension. Arch Intern Med 2005; 165(8): 947-953.
21. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW et al. The effects of dietary
protein restriction and blood-pressure control on the progression of chronic renal disease.
Modification of Diet in Renal Disease Study Group.[see comment]. N Engl J Med 1994; 330(13):
877-884.
22. Anonymous. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular
filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The
NKFM & MDCH 255